The science of delivering cures straight to your cells | Eric Kelsic

Become a Big Think member to unlock expert classes, premium print issues, exclusive events and more: https://ift.tt/cDMxKJN “Until very recently, I thought I would die with the same genome that I was born with.” Subscribe to Big Think on YouTube ► https://www.youtube.com/channel/UCvQECJukTDE2i6aCoMnS-Vg?sub_confirmation=1 Up next, Why 2025 is the single most pivotal year in our lifetime | Peter Leyden ► https://www.youtube.com/watch?v=w5k72A30kUc&vl=en What if the genome you were born with wasn’t fixed? Eric Kelsic, CEO of Dyno Therapeutics, explains how gene therapy is moving from promise to reality, delivering treatments directly to cells and potentially curing diseases for a lifetime. 0:00 The power of genetic technology 1:17 Meet Eric Kelsic 1:31 Making gene therapy mainstream 2:26 Engineering the capsid sequence 4:34 Producing and purifying capsids at scale 7:50 Automating the analysis of patterns 9:55 Permanent cures 10:26 Zolgensma 12:19 Improving cost efficiency in gene therapy Read the video transcript ► https://ift.tt/2dTbNOG © Freethink Media Inc., All Rights Reserved. ---------------------------------------------------------------------------------- Go Deeper with Big Think: ►Become a Big Think Youtube Member Get exclusive classes and early, ad-free access to new releases without leaving Youtube. https://www.youtube.com/@bigthink/membership/ ►Become a Big Think Web Member Get the entire Big Think Class library, premium print issues, live events, and more. https://ift.tt/Rfir1Z3 ►Subscribe to Big Think on Substack Get all of your favorite Big Think content delivered to your inbox. https://ift.tt/0MszUWx ---------------------------------------------------------------------------------- About Eric Kelsic, PhD Prior to founding Dyno, Eric led a team to develop the technology underlying Dyno’s artificial intelligence powered capsid engineering platform in George Church’s lab at the Wyss Institute of Harvard Medical School. There he measured the first comprehensive fitness landscape of the adeno-associated virus (AAV) capsid protein and co-discovered the AAV MAAP gene. He earned a PhD in Systems Biology from Harvard University and a BS in Physics from Caltech. Under Eric’s leadership Dyno has raised over $100M in VC financing, including a 2021 Series A led by a16z and signed partnership with world-leading gene therapy companies (Novartis, Sarepta, Roche, Spark and Astellas). Dyno was named Xconomy’s 2020 Startup of the Year and Eric was recognized as one of Endpoint’s 20 under 40 next-gen biotech leaders in 2021.